atripla
Selected indexed studies
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. (N Engl J Med, 2024) [PMID:39046157]
- Coadministration of ARV (Atripla) and Topiramate disrupts quail cardiac neural crest cell migration. (Birth Defects Res, 2021) [PMID:33484098]
- Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. (Drugs, 2010) [PMID:21080746]
_Worker-drafted node — pending editorial review._
Connections
atripla is a side effect of
Sources
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. (2025) pubmed
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. (2023) pubmed
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. (2020) pubmed
- Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2021) pubmed
- Emtricitabine/tenofovir disoproxil fumarate. (2004) pubmed
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. (2024) pubmed
- Coadministration of ARV (Atripla) and Topiramate disrupts quail cardiac neural crest cell migration. (2021) pubmed
- Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. (2010) pubmed
- Atripla approval in Europe. (2006) pubmed
- Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. (2012) pubmed